Association of FGFR2 and TOX3 Genetic Variants With the Risk of Breast Cancer in Iranian Women
Archives of Breast Cancer · 01.08.2018 · 118-121
DOI: 10.19187/abc.201853118-121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Breast Cancer, erschienen am 01.08.2018. Verfasst von Mojgan Hosseini und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Breast cancer is the most common cause of cancer-related death in women worldwide. Novel genetic markers for breast cancer susceptibility have been identified in population-based studies. The aim of this study was to examine the association of two single-nucleotide polymorphisms (SNPs) of FGFR2 (rs1219648) and TOX3 (rs8051542) with the risk of breast cancer in Iranian women.
Methods
Breast cancer patients (n?=?126) and healthy controls (n?=?160) were genotyped for SNPs in FGFR2 (rs1219648) and TOX3 (rs8051542) using the tetra-primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Also, immunohistochemical tests for human epidermal growth factor receptor-2, estrogen receptor, and progesterone receptor were carried out on breast tumor tissues.
Results
TOX3 (rs8051542) CC (OR?=?1.24; 95% CI, 0.72-0.214; P?
Schlagwörter
Zitieren
APA
Hosseini, M., Houshmand, M., & Froozan, S. (2018). Association of FGFR2 and TOX3 Genetic Variants With the Risk of Breast Cancer in Iranian Women. Archives of Breast Cancer, 118-121. https://doi.org/10.19187/abc.201853118-121
Vancouver
Hosseini M, Houshmand M, Froozan S. Association of FGFR2 and TOX3 Genetic Variants With the Risk of Breast Cancer in Iranian Women. Archives of Breast Cancer. 2018:118-121. doi:10.19187/abc.201853118-121
BibTeX
@article{Hosseini2018,
author = {Hosseini, Mojgan and Houshmand, Massoud and Froozan, Shima},
title = {Association of FGFR2 and TOX3 Genetic Variants With the Risk of Breast Cancer in Iranian Women},
journal = {Archives of Breast Cancer},
year = {2018},
pages = {118--121},
doi = {10.19187/abc.201853118-121}
}
EUVIMED